deltatrials
Terminated PHASE2 NCT00726037

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

A Pilot Study Evaluating the Efficacy of Regulatory T-cell (T-reg) Suppression by Denileukin Diftitox (Ontak) in Metastatic Pancreatic Cancer

Sponsor: Eisai Inc.

Conditions Metastatic Pancreatic Cancer
Interventions Ontak
Updated 9 times since 2017 Last updated: Aug 23, 2016 Started: Oct 31, 2008 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

A PHASE2 clinical study on Metastatic Pancreatic Cancer, this trial is terminated or withdrawn. The trial is conducted by Eisai Inc. and has accumulated 9 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eisai Inc.
  • Loyola University
  • Riveria Country Club Organization
Data source: Loyola University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Maywood, United States